Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, today announced that it has secured a $30 million ...

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study. “Dermatomyositis is a ...

Increased odds of atherosclerotic cardiovascular disease seen in association with cutaneous lupus and systemic lupus, but not psoriasis. HealthDay News — Cutaneous lupus erythematosus (CLE ...

Disitamab vedotin is an antibody–drug conjugate(ADC)comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2 ... We report a case of severe cutaneous drug toxicity ...

Please provide your email address to receive an email when new articles are posted on . Phase 2a interim data show 100% of patients achieving the primary endpoint of skin toxicity improvement.

Most immune cells express the receptors for epinephrine ... is characterized by elevated serum levels of allergen-specific IgE, cutaneous inflammation with infiltration of eosinophils, and ...

12Memorial Sloan Kettering Cancer Center, New York City, New York. *Corresponding Author: Adam J. Schoenfeld, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E-mail: ...

In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread popularity not only as effective agents in the management of type 2 diabetes but also for their beneficial ...